H100 PD Treatment Breakthrough

H100 Peyronie’s Disease Treatment Breakthrough

IRB Clinical Trial – Topical H100™ Peyronie’s Disease Treatment Shows Statistically Significant Improvement in Penile Length, Curvature and Pain. 1

Topically applied (not injected) H100 is most effective when used in the Acute phase of the disease, though it can be utilized in all stages. It is based on Hybrid Medical’s advancement in sub-dermal treatment delivery.  After a decade of research, we developed a Peyronie’s disease treatment that is intended to target inflammation, scar tissue remodeling, and plaque development.

A proprietary and patented combination of plaque-modifying ingredients and an effective transdermal carrier delivers medicine directly into the area of scar tissue. Research shows the ingredients disrupt the inflammatory process and remodel scar tissue which may reduce curvature and pain1. As documented in prior independent studies, Nicardipine and Superoxide dismutase can accomplish this5,6. We combined these ingredients with ultra-purified emu oil which contains the fatty acids necessary to be an effective carrier agent2,3,4.

blood water

Emu oil

  • Oil from the emu bird native to Australia
  • Historically used by Aborigines to treat burns, wounds and scar tissue
  • Shown to be an extremely effective transdermal carrier2
  • May have anti-inflammatory and scar remodeling properties3,4
green health

Nicardipine

  • Shown to be clinically effective when injected into Peyronie’s disease tissue5
RX green

Superoxide Dismutase (SOD)

  • Used to treat inflammatory and other diseases
  • Topically applied SOD has been shown to be effective in Peyronie’s disease studies6
  • H100 Now Available In All 50 States!
    We're proud to announce H100 is now available in all 50 U.S. States! Contact Custom RX to order now!
    H100 Now Available In All 50 States!
  • John A. | Dec 2018
    My experience has been positive. With the 3 month prescription and usage, I estimate that the curvature was reduced by approximately 50% with more than 50% reduction in discomfort/pain with no side effects. Thank you Dr. Twidwell! I hope others are experiencing at least as good or better results than I am!
    John A. | Dec 2018
  • Sean | Oct 2019
    I was diagnosed with Peyronie's disease and was only given a couple of options by my doctor at that time. Treatment options ranged from not doing anything and waiting to see if it got better, to surgery. After taking some pills and waiting for a change I talked to a friend of mine who is a Urologist and he put me in touch with a colleague of his (Dr. Twidwell) that was using a product called H100 to treat Peyronie's . I contacted Dr. Twidwell to get a second opinion on my condition and find out more about H100.  Dr. Twidwell explained that the best time to treat Peyronie's with H100 is in the acute stage of the disease which is in the first 18 months.  I was just past that stage. I decided to do the treatment anyway.  What did I have to lose? After the first three months, my wife and I noticed a decrease in the curvature.  Since I started treatment after the acute phase and had seen a difference, I decided to continue with H100 for a second three month treatment plan. I'm so  glad that I decided to get a second opinion and see Dr. Twidwell.
    Sean | Oct 2019
  • We promise we read every comment!
    Comments? – Contact@HybridMedical.org
    Tell us how your H100 treatment is going – Contact@HybridMedical.org
    Questions for Dr. Twidwell? – Contact@HybridMedical.org
    We promise we read every comment!

 Hear Dr. Twidwell discuss H100 research, ingredients and intended users.

 

How to Properly Apply H100

Abstract of Our Published Clinical Study Results

Int J Impot Res. 2016 Mar-Apr;28(2):41-5. doi: 10.1038/ijir.2015.22. Epub 2015 Dec 24.

Topical treatment for acute phase Peyronie’s disease utilizing a new gel, H-100: a randomized, prospective, placebo-controlled pilot study.

Twidwell J, Levine L.

Abstract

Safety and efficacy of topically applied gel H100 composed of Nicardipine, superoxide dismutase and emu oil for treatment of acute phase Peyronie’s disease (PD) was evaluated. Twenty-two patients (PD <12 months duration) were studied in a prospective, randomized, double-blind, placebo-controlled study. Eleven patients received H100 and 11 patients received placebo for 3 months. All 22 patients then received H100 for the final 3 months. Flaccid-stretched penile length, degree of penile curvature, pain level and side effects were assessed monthly. H100 showed significant improvement in all PD parameters at 6 months: mean stretched penile length increase (22.6%, P=0.0002), mean curvature reduction (40.8%, P=0.0014), and mean pain level reduction (85.7%, P=0.004). Placebo group showed no significant improvement except for mean stretched penile length increase (6.8%, P=0.009). Crossover patients from placebo to H-100 showed significant improvement in all parameters: mean stretched penile length increase (17.5%, P=0.000007), mean curvature reduction (37.1%, P=0.006), and mean pain level reduction (40%, P=0.17). Treatment was well tolerated. A self-limited rash was the only side effect in three patients. Statistically significant improvements in flaccid-stretched penile length, curvature and pain suggest that H100 is a safe and possibly effective non-invasive, topically applied treatment for acute phase Peyronie’s Disease.

The study size was relatively small, but its design was done under the guidance of Dr. Larry Levine, a world expert in Peyronie’s Disease.  Due to H100’s mechanism of action, the study only included acute phase patients with developing disease.

Based on our study, maximum benefit was seen after six months of treatment with H100, though many patients noted improvement after three months of treatment. (1)

A skin rash in the area of application is the only known side effect or adverse reaction in about 10% of patients with H100 use.

No compounded medication is reviewed by the FDA for safety and efficacy.

Important Note:  H100 gel is only meant to be applied topically as directed for treatment of Peyronie’s disease. It is not intended for any other use. Do NOT take it orally, by injection or through any other method of delivery.  For best results, always follow prescribing directions carefully.

  1. J Twidwell, L Levine. Topical treatment for acute phase Peyronie’s disease utilizing a new gel, H-100: a randomized, prospective, placebo-controlled pilot study. International Journal of Impotence Research (2016) 28, 41–45; doi:10.1038/ijir.2015.22.
  2. Zemtsov A, Gaddis M, Montalvo-Lugo V. Moisturizing and Cosmetic Properties of Emu Oil: A Double Blind Study. Australas J Dermatol 1996; 37: 159–161.
  3. Qiu XW, Wang JH, Fang XW, Gong ZY, Li ZQ, Yi ZH. Anti-inflammatory activity and healing-promoting effects of topical application of emu oil on wound in scalded rats. [Article in Chinese]. Di Yi Jun Yi Da Xue Xue Bao 2005; 25: 407–410.
  4. Yoganathan S, Nicolosi R, Wilson T, Handelman G, Scollin P, Tao R et al. Antagonism of croton oil inflammation by topical emu oil in CD-1 mice. Lipids 2003; 38: 603–607.
  5. Soh J, Kawauchi A, Kanemitsu N, Naya Y, Ochial A, Naltoh Y et al. Nicardipine vs saline injection as treatment for Peyronie’s disease: a prospective, randomized, single-blind study. J Sex Med 2010; 7: 3743–3749.
  6. Riedl C, Sternig P, Galle G, Langmann F, Vcelar B, Vorauer K et al. Liposomal recombinant human superoxide dismutase for the treatment of Peyronie’s disease: a randomized placebo-controlled double-blind prospective clinical study. Eur Urol 2005; 48: 656–661.